The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation

计划入组 20 人 · 首次发布于 2010 年 4 月 7 日

Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity

计划入组 50 人 · 首次发布于 2021 年 10 月 15 日

Customized Choice of Oral P2Y12 Receptor Blocker

计划入组 4,000 人 · 首次发布于 2011 年 11 月 23 日

P2Y12 receptor antagonists

P2Y12 antagonists(Shanghai Hengrui Pharmaceuticals)

Cangrelor(Kengreal, Kengrexal)

C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Veru Inc

United States

LRP5 Protein Identified as Novel Target for Safer Antithrombotic Therapies With Reduced Bleeding Risk

CureGene Doses First Participant in U.S. Pivotal Trial of Evategrel, a Novel Dual-Formulation P2Y12 Inhibitor

CureGene's Novel Antiplatelet Therapy CG-0255 Receives Clinical Trial Approval in China